Active ingredients: fluticasone furoate + umeclidinium + vilanterol
What it is used for
Asthma,TRELEGY ELLIPTA is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.,COPD,TRELEGY ELLIPTA is indicated for the maintenance treatment of adults with moderate to severe COPD who require treatment with LAMA+LABA+ICS.,TRELEGY ELLIPTA is not indicated for the initiation of therapy in COPD.
How to take it
The way to take this medicine is: Inhalation.
- Store below 30 degrees Celsius
- Shelf lifetime is 24 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
A plastic inhaler with a light grey body and a beige mouthpiece cover containing two strips of blister each containing a white powder
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Is this medicine subsidised?
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on May 1, 2022. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy?
For the active ingredient fluticasone furoate + umeclidinium + vilanterol
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems